
A Japanese government panel has approved the world's first clinical research using human induced pluripotent stem cells, officials said. The panel of the country's Health Ministry has issued approval for governmental scientific research institute Riken and the Foundation for Biomedical Research and Innovation to conduct a clinical research plan to use iPS cells for retinal regeneration, Kyodo News reported Wednesday. Kyoto University Professor Shinya Yamanaka co-won the 2012 Nobel Prize in physiology or medicine for his development of iPS cells, which can grow into any type of human body tissue and are seen as candidates for regenerative medicine and drug development. The clinical research team will try to develop treatment techniques using iPS cells to cure age-related macular degeneration, a condition that can cause sudden vision loss due to retinal damage. The team said it would extract skin cells from several patients, create iPS cells from them, develop them into pigment epithelium of the retina and transplant them into the patients' retinas. The researchers said they would attempt the transplants next year.
GMT 14:31 2018 Friday ,19 January
Amazon narrows list of 'HQ2' candidates to 20GMT 13:18 2018 Thursday ,18 January
China to step up cryptocurrency crackdownGMT 12:30 2018 Sunday ,14 January
Japan's new crypto-currency crooners sing the bitcoin beatsGMT 13:49 2018 Friday ,12 January
Top European chefs take electric pulse fishing off the menuGMT 11:32 2018 Tuesday ,09 January
Apple urged to shield kids from iPhone addictionGMT 17:27 2017 Tuesday ,19 December
Scientists confirm 3.5 billion-yr-old fossil life in rockGMT 08:31 2017 Friday ,21 July
Samsung heiress ordered to pay $7.6 millionGMT 13:20 2017 Saturday ,29 April
SpaceX to launch classified US govt payload SundayMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor